Importantly, we observed a pronounced decrease in tumor vasculogenic mimicry in the galunisertib-treated xenografts noted by the percentage of PAS-CD34+/PAS+CD34+ cells identified using immunohistochemistry (Fig. 5C, NTC group 0.43 ± 0.07, N = 5 vs. galunisertib-treated group 0.17 ± 0.03, N = 4, P = 0.0085). Here, CD34 is linked to neoplasm.